Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly.See plans and pricing.See plans →
Calocurb raises $27M as revenue triples to $15M, capitalizing on GLP-1 market growth with clinical trial success.
PRIVATESep 08, 2026•about 3 hours ago
Amount Raised
$27 Million
Round Type
Venture - Series Unknown
New ZealandArtificial Intelligence
Description
Calocurb, a wellness company in the GLP-1 space, has raised $27 million in funding as it experiences significant growth momentum. The company's revenue tripled from $5 million to $15 million last year, driven by strong demand in North America. The funding comes on the heels of positive clinical trial results showing weight loss of 4.5kg average with muscle gain, differentiating Calocurb from traditional GLP-1 drugs. CEO Sarah Kennedy expects revenue to double again this year following the release of the company's fourth clinical trial.
Company Information
Company
Calocurb
Location
New Zealand
About
Calocurb is a company that has developed a hops-based hunger suppressant. It aims to target an investment cap raise of $17 million to further its growth and product development. The company seems focused on addressing issues related to appetite control. More detailed information about their mission and product offerings is not provided.
Don't miss Calocurb's next move
Get an email the moment Calocurb raises, hires an exec, or expands, usually minutes after it happens.
New ZealandArtificial Intelligence